Professional Medical Expertise Co. (ProMedEx) reported a profit boost of 83% to SAR 22.1 million for the first half of 2025, compared to SAR 12.1 million in the same period last year.
Item | H1 2024 | H1 2025 | Change |
---|---|---|---|
Revenues | 147.39 | 190.04 | 28.9 % |
Gross Income | 62.60 | 85.06 | 35.9 % |
Operating Income | 17.34 | 27.11 | 56.3 % |
Net Income | 12.11 | 22.10 | 82.5 % |
Average Shares | 3.50 | 3.50 | - |
Earnings Per Share before unusual items (Riyal) | 3.46 | 6.31 | 82.5 % |
EPS (Riyal) | 3.46 | 6.31 | 82.5 % |
Item | H2 2024 | H1 2025 | Change |
---|---|---|---|
Revenues | 163.74 | 190.04 | 16.1 % |
Gross Income | 74.49 | 85.06 | 14.2 % |
Operating Income | 20.66 | 27.11 | 31.2 % |
Net Income | 15.54 | 22.10 | 42.2 % |
Average Shares | 3.50 | 3.50 | - |
Earnings Per Share before unusual items (Riyal) | 4.44 | 6.31 | 42.2 % |
EPS (Riyal) | 4.44 | 6.31 | 42.2 % |
The profit growth was mainly attributed to higher sales in H1 2025, driven by the execution of large supply contracts for customers compared to a year earlier.
Sequentially, earnings also witnessed a 42.2% jump from SAR 15.54 million in H2 2024.
Additional Information:
Shareholders’ equity (with no minority interests) at the end of H1 2025 stood at SAR 131.801 million, compared to SAR 99.335 million at the end of H1 2024.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: